U.S. plans 100% tariffs on imported drugs amid supply chain fragility and monopolistic pricing structures

Indigenous pharmacopeias and traditional medicine systems offer alternatives to patented pharmaceuticals, yet are sidelined by policies prioritizing industrial-scale drug production. The U.S. tariff plan ignores the potential of ethnobotanical knowledge, which has historically provided low-cost, accessible treatments for chronic and infectious diseases. By focusing solely on industrial tariffs, the policy reinforces a colonial model of medicine that extracts resources while marginalizing local knowledge holders.

The U.S. pharmaceutical industry's pricing power traces back to the 1984 Hatch-Waxman Act, which extended patent monopolies and incentivized high-cost drug development. Historical parallels include the 1990s 'drug price crisis' in the U.S., where monopolistic practices led to public outcry and eventual (though limited) reforms like the Inflation Reduction Act. The current tariff proposal risks repeating past mistakes by addressing symptoms rather than structural imbalances in the global drug market.

In Europe, countries like Germany and the Netherlands negotiate drug prices collectively, achieving lower costs than the U.S. by rejecting monopolistic pricing. South Africa's 1997 Medicines Act challenged patent barriers to access generic HIV drugs, setting a precedent for balancing innovation with affordability. The U.S. tariff plan ignores these models, instead doubling down on a protectionist approach that could isolate the country from global best practices in drug pricing and supply chain resilience.

Studies show that high drug prices in the U.S. are driven by patent monopolies rather than R&D costs, with pharmaceutical companies spending more on marketing and share buybacks than innovation. The proposed tariffs could disrupt global supply chains, leading to shortages of critical medicines, as seen during the COVID-19 pandemic when export restrictions exacerbated shortages. Scientific consensus supports diversifying supply chains and reforming patent laws to improve affordability and resilience.

Artistic and spiritual traditions often frame health as a communal rather than commodified resource, challenging the transactional logic of pharmaceutical capitalism. The tariff proposal reflects a mechanistic worldview that prioritizes control and scarcity over holistic, regenerative approaches to medicine. Indigenous and Afro-diasporic spiritual practices, such as those in the Candomblé or Native American traditions, emphasize plant-based healing as part of a broader ecological and cultural ecosystem, which is erased by industrial tariff policies.

If implemented, the tariffs could trigger retaliatory measures from trading partners, leading to a spiral of protectionism that destabilizes global drug supply chains. Scenario modeling suggests that diversifying production to include mid-sized generic manufacturers in Africa and Latin America could reduce U.S. dependence on monopolistic suppliers while improving global access. Long-term, the policy risks entrenching a bifurcated system where wealthy nations hoard innovation while poorer nations face shortages and price hikes.

Low-income patients in the U.S., who already face disproportionate barriers to care, would bear the brunt of higher drug prices resulting from tariffs. Generic drug manufacturers in India and Brazil, which supply 80% of the world's generics, would face severe economic losses, threatening access to medicines in the Global South. Workers in global pharmaceutical supply chains, often in precarious conditions, would face further exploitation as corporations seek to offset tariff costs through labor arbitrage.